Thrombopoietic factors potentially useful in the treatment of acute leukemia

Leukemia Research

Volumn 22, Issue 12, 1998, Pages 1155-1164

  Archimbaud, Eric ^a   Thomas, Xavier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute leukemia; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Interleukin 11; Interleukin 3; Interleukin 6; Stem cell factor; Thrombopoietin

Indexed keywords

CARBOPLATIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 3; INTERLEUKIN 6; MACROGOL; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; MILODISTIM; PACLITAXEL; RECOMBINANT GROWTH FACTOR; STEM CELL FACTOR; THROMBOPOIETIN;

ACUTE LEUKEMIA; ARTHRITIS; BONE PAIN; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER TOXICITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0032438811     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00118-0     Document Type: Article

References (141)

1. Mastriani D.M., Tung N.M., Tenen D.G. Acute myelogenous leukemia: current treatment and future directions. Am J Med. 92:1992;286.
2. Anderlini P., Luna M., Kantarjian H.M., O'Brien S., Pierce S., Keating M.J., Estey E.H. Causes of initial induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 10:1996;600.
3. Tornebohm E., Lockner D., Paul C. A retrospective analysis of bleeding complications in 438 patients with acute leukaemia during the years 1972-1991. Eur J Haematol. 50:1993;160.
4. Gmür J., Burger J., Schanz U., Fehr J., Schaffner A. Safety of stringent platelet transfusion policy for patients with acute leukaemia. Lancet. 338:1991;1223.
5. Bishop M.R., Jackson J.D., O'Kane-Murphy B., Schmit-Pokorny K., Vose J.M., Bierman P.J., Warkentin P.I., Armitage J.O., Garrison L., Kessinger A. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral blood cells. J Clin Oncol. 14:1996;2521.
6. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., Omura G.A., Moore J.O., McIntyre O.R., Frei III E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med. 331:1994;896.
7. Zittoun R.A., Mandelli F., Willemze R., de Witte T., Labar B., Resegotti L., Leoni F., Damasio E., Visani G., Papa G., Caronia F., Hayat M., Stryckmans P., Rotoli B., Leoni P., Peetermans M.E., Dardenne M., Vegna M.L., Petti M.C., Solbu G., Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med. 332:1995;217.
8. Stalfelt A.M., Brodin H., Wadman B. Cost analysis of different phases of acute myeloid leukemia. Leuk Res. 18:1994;783.
9. Lok S., Kaushansky K., Holly R.D., Kuijper J.L., Lofton-Day C.E., Oort P.J., Grant F.J., Heipel M.D., Burkhead S.K., Kramer J.M., Bell L.A., Sprecher C.A., Blumberg H., Johnson R., Prumkard D., Ching A.F.T., Mathewes S.L., Bailey M.C., Forstrom J.W., Buddle M.M., Osborn S.G., Evans S.J., Sheppard F.O., Presnell S.T., O'Hara P.J., Hagen F.S., Roth G.J., Foster D.C. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 369:1994;565.
10. Kaushansky K., Lok S., Holly R.D., Broudy V.C., Lin N., Bailey M.C., Forstrom J.W., Buddle M.M., Oort P.J., Hagen F.S., Roth G.J., Papayannopoulou T., Foster D.C. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 369:1994;568.
11. Bartley T.D., Bogenberger J., Hunt P., Li Y.S., Lu H.S., Martin S., Chang M.S., Samal B., Nichol J.L., Swift S., Johnson M.J., Hsu R.Y., Parker V.P., Suggs S., Skrine J.D., Merewether L.A., Clogston C., Hsu E., Hokom M.M., Hornkohl A., Choi E., Pangelinan M., Sun Y., Mar V., McNinch J., Simonet L., Jacobsen F., Xie C., Shutter J., Chute H., Basu R., Selander L., Trollinger D., Sieu L., Padilla D., Trail G., Elliott G., Zumi R., Covey T., Crouse J., Garcia A., Xu W., Del Castillo J., Biron J., Cole S., Hu M.C.T., Pacifici R., Ponting I., Saris C., Wen D., Yung Y.P., Lin H., Bosselman R.A. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 77:1994;1117.
12. Wendling F., Maraskovsky E., Debili N., Florindo C., Teepe M., Titeux M., Methia N., Breton-Gorius J., Cosman D., Vainchenker W. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 369:1994;571.
13. de Sauvage F.J., Hass P.E., Spencer S.D., Malloy B.E., Gurney A.L., Spencer S.A., Darbonne W.C., Henzel W.J., Wong S.C., Kuang W.J., Oles K.J., Hultgren B., Solberg L.A., Goeddel D.V., Eaton D.L. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 369:1994;533.
14. Choi E.S., Hokom M., Bartley T., Li Y.S., Ohashi H., Kato T., Nochol J.L., Skrine J., Knudten A., Chen J., Hornkohl A., Grampp G., Sleeman L., Cole S., Trail G., Hunt P. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional human platelets in vitro. Stem Cells. 13:1995;317.
15. Angchaisuksiri P., Carlson P.L., Dessypris E.N. Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. Br J Haematol. 93:1996;13.
16. Alexander W.S., Roberts A.W., Nicola N.A., Li R., Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 87:1996;2162.
17. de Sauvage F.J., Carver-Moore K., Luoh S.M., Ryan A., Dowd M., Eaton D.L., Moore M.W. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 183:1996;651.
18. Nichol J.L., Hokom M.M., Hornkohl A., Sheridan W.P., Ohashi H., Kato T., Li Y.S., Bartley T.D., Choi E., Bogenberger, Skrine J.D., Knudten A., Chen J., Trail G., Sleeman L., Cole S., Grampp G., Hunt P. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest. 95:1996;2973.
19. Harker L.A., Marzec U.M., Hunt P., Kelly A.B., Tomer A., Cheung E., Hanson S.R., Stead R.B. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 88:1996;511.
20. Ulich T.R., del Castillo J., Senaldi G., Kinstler O., Yin S., Kaufmlan S., Tarpley J., Choi E., Kirley T., Hunt P., Sheridan W.P. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood. 87:1996;5006.
21. Hokom M.M., Lacey D., Kinstler O.B., Choi E., Kaufman S., Faust J., Rowan C., Dwyer E., Nichol J.L., Grasel T., Wilson J., Steinbrick R., Hecht R., Winters D., Boone T., Hunt P. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 86:1995;4486.
22. Akahori H., Shibuya K., Obuchi M., Nishizawa Y., Tsuji A., Kabaya K., Kusaka M., Ohashi H., Tsumura H., Kato K., Miyazaki H. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol. 94:1996;722.
23. Farese A.M., Hunt P., Grab L.B., MacVittie T.J. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in non human primates after radiation-induced marrow aplasia. J Clin Invest. 97:1996;2145.
24. Molineux G., Hartley C.A., McElroy P., McCrea C., McNiece I.K. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood. 88:1996;1509.
25. Kabaya K., Shibuya K., Torii Y., Nitta Y., Ida M., Akahori H., Kato T., Kusaka M., Miyasaki H. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice. Bone Marrow Transplant. 18:1996;1035.
26. Basser R.L., Rasko J.E.J., Clarke K., Cebon J., Green M.D., Hussein S., Alt C., Menchaca D., Tomita D., Marty J., Fox R.M., Begley G. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 348:1996;1279.
27. Basser R.L., Rasko J.E.J., Clarke K., Cebon J., Green M.D., Grigg A.P., Zaleberg J., Cohen B., O'Byrne J., Menchaca D.M., Fox R.M., Begley C.G. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 89:1997;3118.
28. Fanucchi M., Glaspy J., Crawford J., Figlin R., Garst J., Sheridan W., Menchaca D., Tomita D., Ozer H., Harker L. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. New Engl J Med. 336:1997;404.
29. O'Malley C.J., Rasko J.E.J., Basser R.L., McGrath K.M., Cebon J., Grigg A.P., Hopkins W., Cohen B., O'Byrne J., Green M.D., Fox R.M., Berndt M.C., Begley C.G. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood. 88:1996;3288.
30. Archimbaud E., Ottmann O., Liu Yin J.A., Lechner K., Dombret H., Sanz M.A., Herrmann F., Gruss H., Fenaux P., Ganser A., Heil G., Kanz L., Brugger W., Sims T., Olsen K., Hoelzer D. A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leudaemia (AML): early results. Blood. 88(Suppl 1):1996;447a.
31. Matsumara I., Kanakura Y., Kato T., Ikeda H., Ishikawa J., Horikawa Y., Hashimoto K., Moriyama Y., Tsujimura T., Nishiura T., Miyasaki H., Matsuzawa Y. Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood. 86:1995;703.
32. Matsumara I., Yanakura Y., Ikeda H., Ishikawa J., Yoshida H., Horikawa Y., Nishiura T., Tahara T., Kato T., Miyazaki H., Matsuzawa Y. Coexpression of thrombopoietin and c-mpl genes in human acute myeloblastic leukemia cells. Leukemia. 10:1996;91.
33. Drexler H.G., Quentmeier H. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Leukemia. 10:1996;1405.
34. Quentmeier H., Zaborski M., Graf G., Ludwig W.D., Drexler H.G. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells. Leukemia. 10:1996;297.
35. Broudy V.C., Lin N.L., Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 85:1995;1719.
36. Spivak J.L., Smith R.R.L., Ihle J. Interleukin 3 promotes the in vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest. 76:1985;1713.
37. Messner H.A., Yamasaki K., Jamal N., Minden M.M., Yang Y.C., Wong G.G., Clark S.C. Growth of human hemopoietic colonies in response to recombinant gibon interleukin 3: comparison with human recombinant granulocyte and granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA. 84:1987;6765.
38. Segal G.M., Stueve T., Adamson J.W. Analysis of murine megakaryocyte colony size and ploidy: Effects of interleukin-3. J Cell Physiol. 137:1988;537.
39. Kavnoudias H., Jackson H., Ettlinger K., Bertoncello I., McNiece I., Williams N. Interleukin 3 directly stimulates both megakaryocyte progenitor cells and immature megakaryocytes. Exp Hematol. 20:1992;43.
40. Debili N., Masse J.M., Katz A., Guichard J., Breton-Gorius J., Vainchenker W. Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood. 82:1993;84.
41. Gordon M.S., Hoffman R. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood. 80:1992;302.
42. Carrington P.A., Hill R.J., Stenberg P.E., Levin J., Corash L., Scheurs J., Baker G., Levin F.C. Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis. Blood. 77:1991;34.
43. Stahl C.P., Winton E.F., Monroe M.C., Haff E., Holman R.C., Myers L., Liehl E., Evatt B.L. Differential effects of sequential, simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor megakaryocyte maturation and platelet response in primates. Blood. 80:1992;2479.
44. Ganser A., Lindemann A., Seipelt G., Ottmann O.G., Herrmann F., Eder M., Frisch J., Schulz G., Mertelsmann R., Hoelzer D. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood. 76:1990;666.
45. Lindemann A., Ganser A., Herrmann F., Frisch J., Seipelt G., Schulz G., Hoelzer D., Mertelsmann R. Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol. 9:1991;2120.
46. Biesma B., Willemse P.H.B., Mulder N.H., Sleijfer D.T., Gietema J.A., Mull R., Limburg P.C., Bouma J., Vellenga E., de Vries E.G. Effects of interleukin 3 after chemotherapy for advanced ovarian cancer. Blood. 80:1992;1141.
47. Postmus P.E., Gietema J.A., Damsma O., Biesma B., Limburg P.C., Vellenga E., de Vries E.G. Effects of recombinant interleukin 3 in patients with relapsed small-cell lung cancer treatmed with chemotherapy: a dose-finding study. J Clin Oncol. 10:1992;1131.
48. Younes A., Sarris A., Consoli U., Rodriguez A., McLaughlin P., Huh Y., Starry S., Cabanillas F., Andreeff M. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic and clinical results. Blood. 87:1996;1698.
49. Kudoh S., Sawa T., Kurihara N., Furuse K., Kurita Y., Fukuoka M., Takada M., Takaku F., Ogawa M., Ariyoshi Y. Phase II study of recombinant interleukin-3 administration following carboplatin and etoposide chemotherapy in small cell lung cancer patients. SDZ ILE 964 (IL-3) Study. Cancer Chemother Pharmacol. 38(Suppl):1996;S89.
50. Ganser A., Ottmann O.G., Seipelt G., Lindemann A., Hess U., Geissler G., Maurer A., Frisch J., Schulz G., Mertelsmann R., Hoelzer D. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia. 7:1993;696.
51. Kurzrock R., Talpaz M., Estrov Z., Rosenblum M.G., Gutterman J.U. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol. 9:1991;1241.
52. Nimer S.D., Paquette R.L., Ireland P., Resta D., Young D., Golde D.W. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol. 22:1994;875.
53. Bargetzi M.J., Gluckman E., Tichelli A., Devergie A., Esperou H., Kabata J., Wodnar-Filipowicz A., Nissen C., Speck B., Gratwohl A. Recombinant human interleukin-3 in refractory severe aplastic anaemia: a phase I/II trial. Br J Haematol. 91:1995;306.
54. Wielenga J.J., Vellenga E., Groenewegen A., Sonneveld P., Lowenberg B. Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia. 10:1996;43.
55. Ganser A., Lindemann A., Ottmann O.G., Seipelt G., Hess U., Geissler G., Kanz L., Frisch J., Schulz G., Herrmann F., Mertelsmann R., Hoelzer D. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. Blood. 79:1992;2583.
56. O'Shaughnessy J.A., Venzon D.J., Gossard M., Noone M.H., Denicoff A., Tolcher A., Danforth D., Jacobson J., Keegan P., Miller L., Chow C., Goldspiel B., Cowan K.H. A phase I study of sequential versus concurrent interleukin-3 and granulocyte colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood. 86:1995;2913.
57. Bretti S., Gilleece M.H., Kamthan A., Fitzsimmons L., Hicks F., Rowlands M., Bishop P., Picardo A.M., Dexter T.M., Scarffe J.H. An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte-macrophage colony-stimulating factor. Eur J Cancer. 32A:1996;1171.
58. Fay J.W., Bernstein S.H. Recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma. Semin Oncol. 23(2 Suppl 4):1996;22.
59. Lemoli R.M., Fortuna A., Fogli M., Gherlinzoni F., Rosti G., Catani L., Gozzette A., Miggliano M.C., Tura S. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Exp Hematol. 23:1995;1520.
60. Veldhuis G.J., Willemse P.H., Beijnen J.H., Boonstra H., Piersma H., van der Graaf W.T., de Vries E.G. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin-3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Br J Cancer. 75:1997;703.
61. Wong G.G., Witek-Giannotti J.S., Temple P.A., Kriz R., Ferenz C., Hewick R.M., Clark S.C., Ikebuchi K., Ogawa M. Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol. 140:1988;3040.
62. Leary A.G., Ikebuchi K., Hirai Y., Wong G.G., Yang Y.C., Clark S.C., Ogawa M. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: Comparison with interleukin-1 alpha. Blood. 71:1988;1759.
63. Kimura H., Ishibashi T., Uchita T., Maruyama Y., Friese P., Burstein S.A. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol. 20:1990;19.
64. Ogawa M. Interleukin 6 and haematopoietic stem cells. Res Immunol. 143:1992;749.
65. Ikebuchi K., Wong G.G., Clark S.C., Ihle J.N., Hirai Y., Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hematopoietic progenitors. Proc Natl Acad Sci USA. 84:1987;9035.
66. Ishibashi T., Kimura H., Shikama Y., Uchida T., Kariyone S., Hirano T., Kishimoto T., Takatsuki F., Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74:1989;1241.
67. Hill R.J., Warren M.K., Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest. 85:1990;1242.
68. Patchen M.L., MacVittie T.J., Williams J.L., Schwartz G.N., Souza L.M. Administration of interleukin 6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood. 77:1991;472.
69. Asano S., Okano A., Ozawa K., Nakahata T., Ishibashi T., Koike K., Kimura H., Tanioka Y., Shibuya A., Hirano T., Kishimoto T., Takaku F., Akiyama Y. In vivo effects of recombinant human interleukin-6 in primates: Stimulated production of platelets. Blood. 75:1990;1602.
70. Herodin F., Mestries J.C., Janodet D., Martin S., Mathieu J., Gascon M.P., Pernin M.O., Ythier A. Recombinant glycosylated human interleukin 6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood. 80:1992;688.
71. Zeidler C., Kanz L., Huruck F., Rittmann K.L., Wildfang I., Kadoya T., Mikayama T., Souza L., Welte K. In vivo effects of interleukin 6 on thrombopoiesis in healthy and irradiated primates. Blood. 80:1993;2740.
72. Weber J., Yang J.C., Topalian S.L., Parkinson D.R., Schwartzentruber D.S., Ettinghausen S.E., Gun H., Mixon A., Kim H., Cole D., Levin R., Rosenberg S.A. Phase I trial of subcutaneous interleukin 6 in patients with advanced malignancies. J Clin Oncol. 11:1993;499.
73. Van Gameren M.M., Willemse P.H., Mulder N.H., Limburg P.C., Groen H.J., Vellenga E., de Vries E.G. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood. 84:1994;1434.
74. D'Hondt V., Humblet Y., Guillaume T., Baatout S., Chatelain C., Berliere M., Longueville J., Feyens A.M., De Greve J., Van Oosterom A., Von Graffenried B., Donnez J., Symann M. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. Blood. 85:1995;2347.
75. Clarke D., Johnson P.W., Banks R.E., Storr M., Kinsey S.E., Johnson R., Morgan G., Gordon M.Y., Illingworth J.M., Perren T.J., Selby P.J. Effects of interleukin-6 administration on platelets and haemopoietic progenitor cells in peripheral blood. Cytokine. 8:1996;717.
76. Schuler M., Peschel C., Schneller F., Fichtner J., Farber L., Huber C., Aulitzky W.E. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J Interferon Cytokine Res. 16:1996;903.
77. Stouthard J.M., Goey H., de Vries E.G., de Mulder P.H., Groenewegen A., Pronk L., Stoter G., Sauerwein H.P., Bakker P.J., Veenhof C.H. Recombinant human interleukin-6 in metastatic renal cell cancer: a phase II trial. Br J Cancer. 73:1996;789.
78. Nieken J., Mulder N.H., Buter J., Vellenga E., Limburg P.C., Piers D.A., de Vries E.G. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood. 86:1995;900.
79. Veldhuis G.J., Willemse P.H., Sleijfer D.T., van der Graaf W.T., Groen H.J., Limburg P.C., Mulder N.H., de Vries E.G. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol. 13:1995;2585.
80. Van Doren B., Saez R.A., Burstein S.A., Abang T., George J., Confer D.L. Clinical and laboratory evaluation of recombinant interleukin-6 in autologous bone marrow transplantation. Blood. 84(Suppl 1):1994;96a.
81. Devine S.M., Winton E.F., Holland H.K., Geller R.B., Heffner L.T., Hillyer C.D., Morris L.E., Rodey G.E., Beveridge R., Lynch J., Klein L., Dix S.P., Wingard J.R. Simultateous administration of interleukin-6 (rhIL-6) and Neupogen (rhG-CSF) following autologous bone marrow transplantation (ABMT) for breast cancer (BCA). Blood. 84(Suppl 1):1994;89a.
82. Lazarus H.M., Winton E.F., Williams S.F., Grinblatt D., Campion M., Cooper B.W., Gunn H., Manfreda S., Isaacs R.E. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant. 15:1995;935.
83. Schrezenmeier H., Marsch J.C., Stromeyer P., Muller H., Heimpel H., Gordon-Smith E.C., Raghavacher A. A phase I/II trail of recombinant human interleukin-6 in patients with aplastic anaemia. Br J Haematol. 90:1995;283.
84. Gordon M.S., Nemunaitis J., Hoffman R., Paquette R.L., Rosenfeld C., Manfreda S., Isaacs R., Nimer S.D. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 85:1995;3066.
85. Estey E., Andreeff M. Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia. 9:1995;1440.
86. MacVittie T.J., Farese A.M., Patchen M.L., Myers L.A. Therapeutic efficacy of recombinant interleukin-6 (IL-6) alone and combined with recombinant human interleukin-3 in a nonhuman primate model of high-dose, sublethal radiation-induced marrow aplasia. Blood. 84:1994;2515.
87. Tsuji K., Lyman S.D., Sudo T., Clark S.C., Ogawa M. Enhancement of murine hematopoiesis by synergistic interactions between Steel Factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. Blood. 79:1992;2855.
88. Du X.X., Williams D.A. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood. 83:1994;2023.
89. Paul S.R., Bennett F., Calvetti J.A., Kelleher K., Wood C.R., O'Hara R.M. Jr., Leary A.C., Sibley B., Clark S.C., Williams D.A., Yang Y.C. Molecular cloning of the cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA. 87:1990;7512.
90. Teramura M., Kobayashi S., Hoshino S., Oshimi K., Mizoguchi H. Interleukin 11 enhances human megakaryocytopoiesis in vitro. Blood. 79:1992;327.
91. Yonemura Y., Kawakita M., Masuda T., Fujimoto K., Takatsuki K. Effect of recombinant human interleukin 11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin 6. Blood. 84:1993;16.
92. Orazi A., Cooper R.J., Tong J., Gordon M.S., Battiato L., Sledge G.W. Jr., Kaye J.A., Kahsai M., Hoffman R. Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol. 24:1996;1289.
93. Burstein S.A., Mei R.L., Henthorn J., Friese P., Turner K. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol. 153:1992;305.
94. Neben T.Y., Loebelenz J., Hayes L., McCarthy K., Stoudemire J., Schaub R., Goldman S.J. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood. 81:1993;901.
95. Hawley R.G., Hawley T.S., Fong A.Z., Quinto C., Collins M., Leonard J.P., Goldman S.J. Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11. Proc Natl Acad Sci USA. 93:1996;10297.
96. Du X.X., Keller D., Maze R., Williams D.A. Comparative effects of in vivo treatment using interleukin-11 and stem cell factor on reconstitution in mice after bone marrow transplantation. Blood. 82:1993;1016.
97. Leonard J.P., Quinto C.M., Kozitza M.K., Neben T.Y., Goldman S.J. Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood. 83:1994;1499.
98. Schlerman F.J., Bree A.G., Kaviani M.D., Nagle S.L., Donnelly L.H., Mason L.E., Schaub R.G., Grupp S.A., Goldman S.J. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates. Stem Cells. 14:1996;517.
99. Du X.X., Doerschuk C.M., Orazi A., Williams D.A. Bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal musosal cells after cytoablative therapy. Blood. 83:1994;33.
100. Keith J.C., Albert L., Sonis S.T., Pfeiffer C.J., Schaub R.G. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells. 12(Suppl 1):1994;79.
101. Potten C.S. Interleukin-11 protects the clonogenic stem cells in murine small-intestin crypts from impairment of their reproductive capacity by radiation. Int J Cancer. 62:1995;356.
102. Gordon M.S., McCaskill-Stevens W.J., Battiato L.A., Loewy J., Loesch D., Breeden E., Hoffman R., Beach K.J., Kuca B., Kaye J., Sledge G.W. Jr. A phase I trial of recombinant human interleukin-11 (Neumega thIL-11 growth factor) in woman with breast cancer receiving chemotherapy. Blood. 87:1996;3615.
103. Cairo M.S., Davenport V., Reaman G., Laver J., Kreissman S., Blazar B., Berg S., Patterson F., Kaye J. Accelerated hematopoietic recovery with rhIL-11 following ifosfamide, carboplatin and etoposide administration in children with solid rtumor or lymphoma: preliminary clinical results of a phase I/II trial. Exp Hematol. 24:1996;1104a.
104. ® rhIL-11 in patients with breast cancer after high-dose chemotherapy with bone marrow and peripheral blood stem cell support. Blood. 88(Suppl 1):1996;300a.
105. ® prevents platelet transfusions in up to 4 cycles of dose-intensive chemotherapyin women with breast cancer. Blood. 88(Suppl 1):1996;448a.
106. Tepler I., Elias L., Smith J.W., Hussein M., Rosen G., Chang A.Y.C., Moore J.O., Gordon M.S., Kuca B., Beach K.J., Loewy J.W., Garnick M.B., Kaye J.A. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 87:1996;3607.
107. ® (rhIL-11) to prevent severe chemotherapy-induced thrombocytopenia. Proc Am Soc Clin Oncol. 16:1997;388.
108. Hu J.P., Cesano A., Santoli D., Clark S.C., Hoang T. Effects of interleukin-11 on the proliferation and cell cycle status of myeloid cells. Blood. 81:1993;1586.
109. Zhang X.G., Gu J.J., Lu Z.Y., Yasukawa K., Yancopoulos G.D., Turner K., Shoyab M., Taga T., Kishimoto T., Bataille R., Klein B. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer GP130. J Exp Med. 177:1994;1337.
110. Kobayashi S., Teramura M., Sugawara I., Oshimi K., Mizogushi H. Interleukin-11 acts as an autocrine growth factor for human megakaryoblastic cell lines. Blood. 81:1993;889.
111. Galmiche M.C., Vogel C.A., Delaloye A.B., Schmidt P.M., Healy F., Mach J.P., Buchegger F. Combined effects of interleukin-3 and interleukin-11 on hematopoiesis in irradiated mice. Exp Hematol. 24:1996;1298.
112. Curtis B.M., Williams D.E., Broxmeyer H.E., Dunn J., Farrah T., Jeffery E., Clevenger W., de Roos P., Martin U., Friend D., Craig V., Gayle R., Price V., Cosman D., March C., Park L.S. Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc Natl Acad Sci USA. 88:1991;5809.
113. Bruno E., Briddell R.A., Cooper R.J., Brandt J.E., Hoffman R. Recombinant GM-CSF/IL-3 fusion protein: its effect on in vitro human megakaryocytopoiesis. Exp Hematol. 20:1992;494.
114. Williams D.E., Dun J.T., Park L.S., Frieden E.A., Seiler F.R., Farese A.M., Macvittie T.J. A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys. Biotechnol Ther. 4:1993;17.
115. Gheilmini M., Pettengell R., Coutinho L.H., Testa N., Crowther D. The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer. Br J Haematol. 93:1996;6.
116. Vadhan-Raj S., Papadopoulos N.E., Burgess M.A., Linke K.A., Patel S.R., Hays C., Arcenas A., Plager C., Kudelka A.P., Hittelman W.N., Broxmeyer H.E., Williams D.E., Garrison L., Benjamin R.S. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 12:1994;715.
117. Runowicz C.D., Mandeli J., Speyer J.L., Wadler S., Hochster H., Garrison L., Holland J.F. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer. Am J Obstet Gynecol. 174:1996;1151.
118. Vose J.M., Anderson J.E., Bierman P.J., Appelbaum F.R., Anderson J.R., Garrison L., Lebsack M.E., Armitage J.O. Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. J Clin Oncol. 14:1996;520.
119. O'Shaughnessy J.A., Tolcher A., Riseberg D., Venzon D., Zudjewski J., Noone M., Gossard M., Danforth D., Jacobson J., Chang V., Goldspiel B., Keegan P., Giusti R., Cowan K.H. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood. 87:1996;2205.
120. Vose J.M., Pandite A.N., Beveridge R.A., Geller R.B., Schuster M.W., Anderson J.E., LeMaistre C.F., Ahmed T., Granena A., Keating A., Fernandez Ranada J.M., Stiff P.J., Tabbara I., Longo W., Copelan E.A., Nochols C., Smith A., Topolsky D.L., Bierman P.J., Lebsack M.E., Lange M., Garrison L. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non Hodgkin's lymphoma: results of a randomized double-blind trial. J Clin Oncol. 15:1997;1617.
121. Ishibashi T., Kimura H., Shikama Y., Uchida T., Kariyone S., Murayama Y. Effect of recombinant granulocyte-macrophage colony-stimulating factor on murine thrombocytopoiesis in vitro and in vivo. Blood. 75:1990;1433.
122. Vadhan-Raj S., Keating M., LeMaistre A., Hittelman W.N., McCredie K., Trujillo J.M., Broxmeyer H., Henney C., Gutterman J.U. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. New Engl J Med. 317:1987;1545.
123. Antin J.H., Smith B.R., Holmes W., Rosenthal D.S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood. 72:1988;705.
124. Ganser A., Völkers B., Greher J., Ottmann O.G., Walther F., Becher R., Bergmann L., Schulz G., Hoelzer D. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplasticc syndromes - A phase I/II trial. Blood. 73:1989;31.
125. Herrmann F., Lindemann A., Klein H., Lübbert M., Schulz G., Mertelsmann R. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia. 3:1989;335.
126. Thompson J.A., Lee D.J., Kidd P., Rubin E., Kaufmann J., Bonnem E.M., Fefer A. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol. 7:1989;629.
127. Terpstra W., Löwenberg B. Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia. 11:1997;315.
128. Hunt P., Zsebo K.M., Hokom M.M., Hornkohl A., Birkett N.C., Del Castillo J.C., Martin F. Evidence that stem cell factor is involved in the rebound thrombocytosis that follows 5-fluorouracil treatment. Blood. 80:1992;904.
129. Andrews R.G., Knitter G.H., Bartelmez S.H., Langley K.E., Farrar D., Hendren R.W., Appelbaum F.R., Bernstein I.D., Zsebo K.M. Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. Blood. 78:1991;1975.
130. Chow F.P., Zsebo K., Hamburger A.W. Effects of in vivo administration of stem cell factor on thrombopoiesis in normal and immunodeficient mice. Exp Hematol. 21:1993;1255.
131. Briddell R.A., Bruno E., Cooper R.J., Brandt J.E., Hoffman R. Effect of c-kit ligand on in vitro human megakaryocytopoiesis. Blood. 78:1991;2854.
132. Tanaka R., Koike K., Imai T., Shiohara M., Kubo T., Amano Y., Komiyama A., Nakahata T. Stem cell factor enhances proliferation, but not maturation of murine megakaryocytic progenitors in serum-free culture. Blood. 80:1992;1743.
133. Costa J.J., Demetri G.D., Harrist T.J., Dvorak A.M., Hayes D.F., Merica E.A., Menchaca D.M., Gringeri A.J., Schwartz L.B., Galli S.J. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med. 183:1996;2681.
134. Weaver A., Ryder D., Crowther D., Dexter T.M., Testa N.G. Increased numbers of long-term culture initiating cells in the apheresis product of patient randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood. 88:1996;3323.
135. Moskowitz C.H., Stiff P., Gordon M.S., McNiece I., Ho A.D., Costa J.J., Broun E.R., Bayer R.A., Wyres M., Hill J., Jelaca-Maxwell K., Nichols C.R., Brown S.L., Nimer S.D., Gabrilove J. Recombinant methionyl human stem cell factor and filgrastin for peripheral blood progenitor cell mobilization and transplantation in non Hodgkin's lymphoma patients. Results of a phase I/II trial. Blood. 89:1997;3136.
136. Starnes H.F. Biological effects and possible clinical applications of interleukin 1. Semin Hematol. 28(Suppl 2):1991;34.
137. Kimura H., Ishibashi T., Shikama Y., Okano A., Akiyama Y., Uchida T., Maruyama Y. Interleukin-1β (IL-1β) induces thrombocytosis in mice: Possible implication of IL-6. Blood. 76:1990;2493.
138. Kovacs C.J., Powell D.S., Evans M.J., Thomas-Patterson D., Johnke R.M. Enhanced platelet recovery in myelosuppressed mice treated with interleukin-1 and macrophage colony-stimulating factor: potential interactions with cytokines having megakaryocyte colony-stimulating activity. J Interferon Cytokine Res. 16:1996;187.
139. Smith J.W., Longo D.L., Alford W.G., Janik J.E., Sharfman W.H., Gause B.L., Curti B.D., Creekmore S.P., Holmlund J.T., Fenton R.G., Sznol M., Miller L.L., Shimizu M., Oppenheim J.J., Fiem S.J., Hursey J.C., Powers G.C., Urba W.J. The effects of treatment with Interleukin 1α on platelet recovery after high-dose carboplatin. New Engl J Med. 328:1993;756.
140. Hatake K., Izumi T., Imagawa S., Ohta M., Miura Y. Macrophage colony-stimulating factor and platelet recovery after chemotherapy. Lancet. 341:1993;963.
141. Khwaja A., Yong K., Jones H.M., Chopra R., McMillan A.K., Goldstone A.H., Patterson K.G., Matheson C., Ruthven K., Abramson S.B., Linch D.C. The effect of macrophage colony-stimulating factor on haemopoietic recovery after autologous bone marrow transplantation. Br J Haematol. 81:1992;288.